Steven D. Nathan, MD, Athol U. Wells, MD, and Rajan Saggar, MD discuss the following:

  • What are the signs and symptoms that a patient with IIP might have PH
  • Studies from 2014 positive takeaways, limitations, and lessons learned
  • Clinical trials


CME/CE Information

Activity Title Diagnosis and Treatment of Idiopathic Interstitial Pneumonia (IIP) – Pulmonary Hypertension (PH)
Topic Idiopathic Pulmonary Fibrosis
Accreditation Type AMA PRA Category 1 Credits™
Release Date July 2015
Expiration Date July 31, 2016
Estimated Time to Complete Activity 30 minutes


Upon completion of the activity, participants should be able to:

  • Identify presenting signs and symptoms that may indicate the presence of PH in a patient with an IIP
  • Explain key test results that can help to confirm a PH diagnosis
  • Review data from studies evaluating treatments for PH in patients with IIPs/IPF


Steven D. Nathan (Chair)
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia

Rajan Saggar, MD
Associate Professor of Medicine
Director, Medical Intensive Care Unit Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs
David Geffen School of Medicine, UCLA
Los Angeles, California

Athol U. Wells, MD
Interstitial Lung Disease Unit
Royal Brampton Hospital
London, UK


  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice, the perception of commercial bias, and whether or not the objectives were met.
  6. Your CME/CE certificate will be available for download.



This activity is provided by The France Foundation.


This activity is intended for pulmonologists, cardiologists, internists, and other healthcare professionals who are managing PH patients.


This education is designed to address knowledge and competence gaps identified for clinicians in the recognition and diagnosis of IIP-PH as well as explore emerging research within the field.


The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The France Foundation designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty have indicated relationships with industry relevant to the content of this CME activity:

  • Steven D. Nathan, MD, FCCP, has received grants/research support from Actelion, Boehringer Ingelheim, Intermune, United Therapeutics, and Veracyte. He has served as a consultant for Actelion, Bayer Pharmaceuticals, Boehringer Ingelheim, Gilead Sciences, Intermune, Roche, and United Therapeutics. He has also received honoraria from Actelion, Gilead Sciences, and United Therapeutics.
  • Rajan Saggar, MD, has received grants/research support from Actelion, Bayer, Gilead Sciences, and United Therapeutics.
  • Athol U. Wells, MD, has served as a consultant for Actelion, Bayer, Boehringer Ingelheim, Chiesi, Genentech, Gilead, Roche/Intermune, and MedImmune. He has received honoraria from Actelion, Bayer, Boehringer Ingelheim, and Roche/Intermune.


The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


This activity is supported by an educational grant from Bayer Global.


The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who has been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Bayer Global assume no liability for the information herein.


Copyright © 2015 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.


The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at


If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..